Amgen (AMGN) Common Equity (2009 - 2026)
Amgen (AMGN) posted quarterly Common Equity of $9.2 billion for Q1 2026, up 48.06% year-over-year from $6.2 billion in Q1 2025, and up 6.14% quarter-over-quarter from $8.7 billion in Q4 2025.
Amgen (AMGN) Common Equity (2009 - 2026) Analysis & Trends
Amgen's Common Equity history runs 18 years deep, the most recent figure standing at $9.2 billion for Q1 2026.
- In Q1 2026, Common Equity rose 48.06% year-over-year to $9.2 billion; the TTM figure through Mar 2026 stood at $9.2 billion (up 48.06% YoY), while the FY2025 annual figure was $8.7 billion, up 47.32% from the prior year.
- Common Equity for Q1 2026 stood at $9.2 billion, up from $8.7 billion in the prior quarter.
- The five-year high for Common Equity was $9.6 billion in Q3 2025, with the low at $916.0 million in Q1 2022.
- The 5-year median for Common Equity is $6.2 billion (2025), against an average of $6.0 billion.
- The sharpest annual moves came in 2022 and 2023: Common Equity sank 90.19% in 2022, then surged 483.84% in 2023.
- Amgen's Common Equity stood at $3.7 billion in 2022, then surged by 70.23% to $6.2 billion in 2023, then retreated by 5.7% to $5.9 billion in 2024, then surged by 47.32% to $8.7 billion in 2025, then rose by 6.14% to $9.2 billion in 2026.
- Business Quant data shows AMGN's Common Equity at $9.2 billion in Q1 2026, $8.7 billion in Q4 2025, and $9.6 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.37 Bn | 632.61 Bn | 17.26 Bn | 84.97 Bn |
| 2 | AbbVie | 469.65 Bn | 463.08 Bn | 12.70 Bn | -5.94 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 106.07 Bn |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | 41.95 Bn |
| 5 | Astrazeneca | 258.06 Bn | 253.16 Bn | 12.86 Bn | 50.37 Bn |
| 6 | Amgen | 236.35 Bn | 222.36 Bn | 7.24 Bn | 11.69 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 11.83 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 85.49 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 23.05 Bn |
| 10 | Sanofi | 55.20 Bn | 47.82 Bn | 10.79 Bn | 80.86 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.69 Bn |
| Mar 31, 2026 | 9.19 Bn |
| Dec 31, 2025 | 8.66 Bn |
| Sep 30, 2025 | 9.62 Bn |
| Jun 30, 2025 | 7.43 Bn |
| Mar 31, 2025 | 6.21 Bn |
| Dec 31, 2024 | 5.88 Bn |
| Sep 30, 2024 | 7.53 Bn |
| Jun 30, 2024 | 5.93 Bn |
| Mar 31, 2024 | 5.02 Bn |
| Dec 31, 2023 | 6.23 Bn |
| Sep 30, 2023 | 7.66 Bn |
| Jun 30, 2023 | 6.78 Bn |
| Mar 31, 2023 | 5.35 Bn |
| Dec 31, 2022 | 3.66 Bn |
| Sep 30, 2022 | 3.65 Bn |
| Jun 30, 2022 | 2.42 Bn |
| Mar 31, 2022 | 916.00 Mn |
| Dec 31, 2021 | 6.70 Bn |
| Sep 30, 2021 | 8.22 Bn |